Clinical Trial

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia

Study acronym: HALF
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluation of the efficacy and safety of withdrawal of tyrosine kinase inhibitors after previous two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-10-29; most recent amendment 2024-11-22.
Status change: Recruiting → Active, Not Recruiting 2023-07-04
Status change: Not Yet Recruiting → Recruiting 2020-09-01
Trial Details
NCT Number NCT04147533
Lead Sponsor Masaryk University
Conditions Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug
Enrollment 150 participants
Start Date 2020-06-16
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2024-11-26